Compare ALCO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | CERS |
|---|---|---|
| Founded | 1960 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 276.0M |
| IPO Year | N/A | 1997 |
| Metric | ALCO | CERS |
|---|---|---|
| Price | $36.61 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 35.3K | ★ 1.6M |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $44,066,000.00 | ★ $199,191,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $24.76 | $1.12 |
| 52 Week High | $38.40 | $2.26 |
| Indicator | ALCO | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 56.10 |
| Support Level | $35.94 | $2.00 |
| Resistance Level | $38.40 | $2.21 |
| Average True Range (ATR) | 0.86 | 0.14 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 24.56 | 52.22 |
Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.